Our lab and clinical experience improve integration, novel potentiation and safety of standard, new drugs and immunotherapy. We have designed extra novel safer options that offer better first and extra second 3rd and 4th chances to have complete remissions and extra quality years of life.
Truly Personalized Medicine Enabled by Innovation built on evidence see progress report 1000 patients
Our personalized medicine integrates information about each individual patient's specialized interpretation of tumor genetics vulnerability but considers more than the disease, To maximize care.we consider both the patients safety requirements, and measures to improve preserve antitumor immune function
Both tumor and patient goals, experiences based and proven , differentiates us from other oncology practices.
Others' "personalized medicine" match a patient's specific tumor mutation to a particular drug. We takes patient care to a more tailored level. Better use of tumor test findings we also consider safety, potentiation of the drug three ways at once and integration in a comprehensive plan. We consider, and don't burn, future options HB pioneered the methods see below
Extensive experience discovered better options when standard therapy predictably produces poor results. We consider patient history, prior treatments, age, and drug tolerance Safety and quality of life considerations identify the personal best chemotherapy. Our lab tested clinically proven innovative approach of combining multiple active cancer drugs in low doses leads to :
- Increased effectiveness. Better multiple partner drugs improve- potentiate anti tumor benefit safely
- Reduced toxicity. Four drugs are less toxic than 1-2 standard drugs We avoid 20-40% rates of severe complications
- Revitalizing failed drugs. See how we reverse resistance We refined and combined methods discovered in many leading labs
- Successful surgery. HB pioneered the concept new three added methods triple chances to shrink tumors > ideal surgery
- Better response rates. And quality of responses. our novel sequential treatments add cumulative multiple responses.
- Improved survival. Added years confirmed see progress report, specific tumors, both untreated high risk and resistant
Our proven innovative approach is unparalleled - combining multiple drugs at low doses to target inhibit multiple cancer resistance pathways simultaneously and generate multiple synergistic potentiator drug to drug interactions., thus enhancing the efficacy of and single drug or drug pair while minimizing toxicity by using low doses.Each drug has 3-4 potentiator drugs that safely improve the inhibition of tumors.
Our record: median survival has increased 2-4 fold versus historical controls in 9 difficult to treat cancers such as pancreatic, cholangio, and gastric carcinomas- also applies to vulnerable and elderly patients. See ASCO 08,11 & Anticancer Research 16,18
We work with you and give you extras - added to standard treatments clinical trials and innovatations each tested - proven step tailored to the patient's tumor genetics and strengths.
The practice pioneered
Lab discoveries and gained unique clinical experience. Drug dose reduction and simultaneous reversal of resistance.
Tracking and software to predict and avoid complications.
Tumor markers: better utilization, creates more options; avoids false leads, facilitates efficient, less costly radiology tests and intervention: HB was Among the first academic users of CEA and CA-125
Prognostication: Published (first) standard lab test sets, methods which better predict survival and avoid false ineligibilty - refusal to treat. Now expanded experience applicable to added cancers.
Choice of drugs, innovations in tumor testing, largest applied experience with third generation applications:
1. Solve drug resistance rather than reject standard drug (improve the standard)
2. Select drugs based on added multiple experience-tested criteria, not simply best standard
3. Prioritize safety, low dosages and multiplication of chances to produce a favorable drug interaction (game theory applied to choices)
4. Miniaturize biopsies, less invasive option, cost effective, focused efficient objectives
5. Triage and identify best action among potentiate genomic proteomic test positives & reverse resistance to test regects
We don't throw away drugs We use them again in even better fashion
|
|
|
